The application of fibroblast activation protein (FAP) in cancer-associated fibroblast (CAF) has garnered widespread attention in nuclear medicine. FAP is highly expressed in most cancer tissues and rarely expressed in healthy tissues. Therefore

radionuclide probes targeting FAP have significant diagnostic and therapeutic potential. Compared to

18

F-FDG

widely used in clinical practice

FAP-targeted tracers exhibit superior target-to-background ratio (tumor-to-background ratio) across various indications. Unlike

18

F-FDG

the c

linical use of FAP-targeted tracers does not require complex preparations like dietary restrictions for patients and offers the possibility of radioligand therapy (RLT). While radiolabeled antibodies have been studied clinically since the 1990s

the introduction and clinical application of FAPI tracers in 2018 marked a breakthrough event in the development of FAP-targeted probes within nuclear medicine. Since then

the development and application of targeted FAP tracers have become a hot topic amongpharmaceutical companies as well as within the radiopharmaceutical and nuclear medicine communities. This article reviewed the current status and research progress of FAP-targeted radiopharmaceuticals.